Cargando…

Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma

CONTEXT: Measurements of plasma methoxytyramine, the O-methylated dopamine metabolite, are useful for detecting rare dopamine-producing pheochromocytomas and paragangliomas (PPGLs) and head and neck paragangliomas (HNPGLs), but utility for screening beyond that achieved using standard measurements o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, Dipti, Peitzsch, Mirko, Prejbisz, Aleksander, Hanus, Katarzyna, Fassnacht, Martin, Beuschlein, Felix, Brugger, Christina, Fliedner, Stephanie, Langton, Katharina, Pamporaki, Christina, Gudziol, Volker, Stell, Anthony, Januszewicz, Andrzej, Timmers, Henri J L M, Lenders, Jacques W M, Eisenhofer, Graeme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488393/ https://www.ncbi.nlm.nih.gov/pubmed/28476870 http://dx.doi.org/10.1530/EJE-17-0077

Ejemplares similares

Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine
por: Richter, Susan, et al.
Publicado: (2022)

Plasma free metanephrine, normetanephrine, and 3-methoxytyramine for the diagnosis of pheochromocytoma/paraganglioma
por: Gupta, Poonam, et al.
Publicado: (2015)

Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging
por: Rogowski-Lehmann, Natalie, et al.
Publicado: (2018)

Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion
por: Li, Minghao, et al.
Publicado: (2021)

Optimized procedures for testing plasma metanephrines in patients on hemodialysis
por: Pamporaki, Christina, et al.
Publicado: (2021)

Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension
por: Constantinescu, Georgiana, et al.
Publicado: (2020)

Dual-Template Magnetic Molecularly Imprinted Polymer for Simultaneous Determination of Spot Urine Metanephrines and 3-Methoxytyramine for the Diagnosis of Pheochromocytomas and Paragangliomas
por: Zeng, Hongyu, et al.
Publicado: (2022)

Silent pheochromocytoma and paraganglioma: Systematic review and proposed definitions for standardized terminology
por: Constantinescu, Georgiana, et al.
Publicado: (2022)

Urinary Free Metanephrines for Diagnosis of Pheochromocytoma and Paraganglioma
por: Ahn, Jiyeon, et al.
Publicado: (2021)

Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma
por: Bliziotis, Nikolaos G., et al.
Publicado: (2021)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Update on Modern Management of Pheochromocytoma and Paraganglioma
por: Lenders, Jacques W. M., et al.
Publicado: (2017)

Metabolome-guided genomics to identify mutations in isocitrate dehydrogenase, fumarate hydratase and succinate dehydrogenase genes in pheochromocytoma and paraganglioma
por: Richter, Susan, et al.
Publicado: (2018)

Metanephrine and normetanephrine associated with subclinical myocardial injuries in pheochromocytoma and paraganglioma
por: Yu, Yang, et al.
Publicado: (2022)

A high sensitivity LC-MS/MS method for measurement of 3-methoxytyramine in plasma and associations between 3-methoxytyramine, metanephrines, and dopamine
por: Smy, Laura, et al.
Publicado: (2021)

THU612 SDHx Pheochromocytoma/Paraganglioma Has Elevation Of Arginine And Lysine Metabolites
por: Ghayee, Hans Kumar, et al.
Publicado: (2023)

Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma
por: Eisenhofer, Graeme, et al.
Publicado: (2022)

Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses
por: Fischer, Alessa, et al.
Publicado: (2023)

Measurements of Plasma-Free Metanephrines by Immunoassay Versus Urinary Metanephrines and Catecholamines by Liquid Chromatography with Amperometric Detection for the Diagnosis of Pheochromocytoma/Paraganglioma
por: Raber, Wolfgang, et al.
Publicado: (2020)

Evaluation of Head and Neck Paragangliomas by Computed Tomography in Patients with Pheochromocytoma-Paraganglioma Syndromes
por: Michałowska, Ilona, et al.
Publicado: (2016)

Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches
por: Gieldon, Laura, et al.
Publicado: (2019)

An LC-MRM assay for the quantification of metanephrines from dried blood spots for the diagnosis of pheochromocytomas and paragangliomas
por: Richard, Vincent R., et al.
Publicado: (2020)

Cabergoline reduces 3-methoxytyramine in a SDHC patient with metastatic paraganglioma and prolactinoma
por: Hussein, Ziad, et al.
Publicado: (2021)

Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma—Experiences From the GPOH-MET Registry
por: Kuhlen, Michaela, et al.
Publicado: (2022)

MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors
por: Ghayee, Hans Kumar, et al.
Publicado: (2020)

Metastatic pheochromocytoma to liver without elevation of metanephrines and catecholamines()
por: López-Gómez, Javier, et al.
Publicado: (2016)

Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
por: Calsina, Bruna, et al.
Publicado: (2023)

Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism
por: Eisenhofer, Graeme, et al.
Publicado: (2020)

Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background
por: Ullrich, Martin, et al.
Publicado: (2019)

Cancer Stem Cells in Pheochromocytoma and Paraganglioma
por: Scriba, Laura D., et al.
Publicado: (2020)

Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status
por: Eisenhofer, Graeme, et al.
Publicado: (2017)

Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review
por: Li, Minghao, et al.
Publicado: (2021)

Correction to: Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review
por: Li, Minghao, et al.
Publicado: (2021)

Pheochromocytoma with Negative Metanephrines: A Rarity and the Significance of Dopamine Secreting Tumors
por: Bozin, Michael, et al.
Publicado: (2017)

Response to Letter to the Editor from Berends et al: “Approach to the Patient: Perioperative Management of the Patient With Pheochromocytoma or Sympathetic Paraganglioma”
por: Berends, Annika M A, et al.
Publicado: (2020)

Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
por: Zhang, Liang, et al.
Publicado: (2023)

Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma
por: Berends, Annika M.A., et al.
Publicado: (2019)

Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas–Effect of Different Statins on Mouse Pheochromocytoma Cells
por: Fliedner, Stephanie M. J., et al.
Publicado: (2014)

FRI217 False Negative Plasma Metanephrines In A Patient With A Bladder Paraganglioma
por: King, Thomas F J, et al.
Publicado: (2023)

Pheochromocytomas and secreting paragangliomas
por: Plouin, Pierre-François, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_cqloot1qd218rt9sq7jk0t72a2